Lilly's Alzheimer's drug gets UK nod, but no NHS funding

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.